A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: Cancer and Leukemia Group B study 89903

Annals of Surgical Oncology

Volumn 15, Issue 1, 2008, Pages 158-164

  Posner, Mitchell C ^a   Niedzwiecki, Donna ^b   Venook, Alan P ^c   Hollis, Donna R ^b   Kindler, Hedy L ^a   Martin, Edward W ^e   Schilsky, Richard L ^a   Goldberg, Richard M ^d  

^a UNIVERSITY OF CHICAGO   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Colorectal cancer; Immunotherapy; Liver metastases

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN VACCINE; CEAVAC; FLUOROURACIL; HUMAN MILK FAT GLOBULE ANTIBODY; IDIOTYPIC ANTIBODY; MILK FAT; MONOCLONAL ANTIBODY; TRIAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ADAPTIVE IMMUNITY; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER IMMUNIZATION; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CLINICAL TRIAL; COLORECTAL CANCER; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; DIZZINESS; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INJECTION SITE REACTION; LIVER LOBECTOMY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE PERIOD; PROTEIN EXPRESSION; SURGICAL TECHNIQUE; TREATMENT DURATION; VEIN THROMBOSIS; VOMITING; WOUND INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTI-IDIOTYPIC; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GLYCOLIPIDS; GLYCOPROTEINS; HEPATECTOMY; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; VACCINATION;

EID: 38049103772     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9654-7     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2007;57(1):43-66
2. Scheele J, Stangl R, Attendorf-Hoffman A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 1990;77(11):1241-6
3. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42
4. Lupinacci R, Penna C, Nordlinger B. Hepatectomy for resectable colorectal cancer metastases-indicators of prognosis, definition of resectability, techniques and outcomes. Surg Oncol Clin N Am 2007;16(3):493-506
5. Pawlik TM, Choti MA. Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg 2007;11(8):1057-77
6. Kornprat P, Jarnagin WR, Gonen M, et al. Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy. Ann Surg Oncol 2007; 19(3):1151-60
7. Jaeck D, Bachellier P, Guiguet M, et al. Long-term survival following resection of colorectal hepatic metastases. Association Francaise de Chirurgie. Br J Surg 1997;84(7):977-80
8. Fong Y, Cohen AM, Fortner JG. Liver resection for colorectal metastases. J Clin Oncol 1997;15(3):938-46
9. Portier G, Elias D, Bouche O, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006;24(31):4976-82
10. Lindenmann J. Speculations on idiotypes and homobodies. Ann Immunol 1973;124(1):171-84
11. Jerne NK. Towards a network theory of the immune system. Ann Immunol 1974;125C(1-2):373-89
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81
13. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004;240(4):644-58
14. Riethmuller G, Holz E, Schlimok G., et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998;16(5):1788-94
15. Colacchio TA, Niedzwiecki D, Camptor C, et al. Phase III trial of adjuvant immunotherapy with MOAb 17-1A following resection for stage II adenocarcinoma of the colon (CALGB 9581). Proc Am Soc Clin Oncol 2004; 23 (abstract 3522), p251
16. Harris JE, Ryan L, Hoover JC Jr, Stuart RK, et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E 5283. J Clin Oncol 2000;18(1):148-57
17. Vermorken JB, Claessen AM, van Titeren H, et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 1999;353(9150):345-50
18. Foon KA, John WJ, Chakraborty M, et al. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. Clin Cancer Res 1997;3(8):1267-76
19. Foon KA, John WJ, Chakraborty M, et al. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics carcinoembryonic antigen. J Clin Oncol 1999;17(9):2889-95
20. Reece De Foon KA, Bhattarcharya-Chatterjee M. Use of the anti-idiotype breast cancer vaccine 11D10 in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer. Clin Breast Cancer 2003;3(Suppl 4):S152-7